Innovation deficit in the pharmaceutical industry

Drug Information Journal

Volumn 30, Issue 1, 1996, Pages 97-108

  Drews, Jürgen ^a,b   Ryser, Stefan ^b  

^a International Research   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Biotech industry; Consolidation; Drug discovery; Genomics; New chemical entitles; Novel compounds

Indexed keywords

MONOCLONAL ANTIBODY; NEW DRUG; RECOMBINANT PROTEIN;

BIOTECHNOLOGY; DRUG INDUSTRY; DRUG SYNTHESIS; GENE THERAPY; PRIORITY JOURNAL; REVIEW;

EID: 0030040773     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000113     Document Type: Review

References (17)

1. Keeling P. Research and Development Demystified in Pursuit of Innovation. Pharma Bus News. 1995;12-16.
2. Do We Pay Too Much for Prescriptions? Consum Rep. 1993:668-674.
3. Schondelmeyer S. Competition and Pricing Issues in the Pharmaceutical Market. PRIME Institute, College of Pharmacy, University of Minnesota, Minneapolis, MN (USA), August 1994.
4. Special Committee on Aging, United States Senate: Earning a Failing Grade: A Report Card on the 1992 Drug Manufacturer Price Inflation, February 1993.
5. Parexel's Pharmaceutical R&D Statistical Sourcebook 1995. Parexel International Corporation; 1995.
6. Pharmaceutical Company League Tables 1994, Scrip Reports. PJB Publications Ltd.; 1994.
7. Prous JR. The Year's New Drugs. Drug News Perspect. 1993;6(2):95-106; 1994;7(1):26-36; 1995;8(1):24-37.
8. Prous JR. The Year's New Drugs. Drug News Perspect. 1993;6(2):95-106; 1994;7(1):26-36; 1995;8(1):24-37.
9. Prous JR. The Year's New Drugs. Drug News Perspect. 1993;6(2):95-106; 1994;7(1):26-36; 1995;8(1):24-37.
10. Struck M. Biopharmaceutical R&D Success Rates and Development Times. Bio/Tech. 1994; 12:674-677.
11. Top 50 Biotech Companies. Montclair, NJ: POV Inc.; 1994.
12. Characterization of Research Effectiveness. A confidential report prepared for Hoffmann-La Roche by The Wilkerson Group, Inc., July 27, 1995.
13. Edwards M. Survey of alliances and INDs of major medical biotechnology companies. Recombinant Capital, Inc.; 1993.
14. Biotech '95: The Ernst & Young Ninth Annual Report on Biotechnology Industry. Ernst & Young, LLP; 1994.
15. Schumpeter J. Business Cycles: Theoretical, Historical and Statistical Analysis of the Capitalist Process. New York: McGraw Hill; 1939.
16. Kevles J, Hood L, eds. The Code of Codes. Scientific and social issues in the Human Genome Project. Cambridge, MA London: Harvard University Press; 1992.
17. Collins J, Driesel AJ, eds. Genome Analysis: From Sequence to Function. BioTech Forum (BTF) 6, Advances in Molecular Genetics, Huthig Buch Verlag GmbH, Heidelberg; 1991.